Novartis: positive phase III data in leukemia
According to this analysis, its Scemblix (asciminib) showed major molecular response (MMR) rates superior to those of standard tyrosine kinase inhibitors (TKIs) at week 48, thus meeting its primary endpoints.
Novartis adds that Scemblix demonstrated a favorable safety and tolerability profile with fewer adverse events and treatment interruptions compared to standard TKIs, and that no new safety signals were observed.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction